VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
guanfacine-ER
Phase 2
Small molecule
Y
Yale University
1
Indications
3
Total Trials
1
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Alcohol Use Disorders
Recruiting
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Alcohol Use Disorders
Phase 2
Recruiting
Clinical
Trials by Indication
[1]
Smoking Cessation
1 trial
Combining Varenicline and Guanfacine for Smoking Cessation
Completed
·
Y
Yale University
·
Phase 2
·
NCT04198116
·
165 enrolled
Alcohol Use Disorders
1 trial
Mechanistic Evaluation of Guanfacine on Drinking Behavior in Women and Men With Alcohol Use Disorders
Recruiting
·
Y
Yale University
·
Phase 2
·
NCT03764098
·
160 enrolled
Cannabis Use
1 trial
A Randomized Controlled Trial of Guanfacine-er for Cannabis Use Disorder
Completed
·
N
New York State Psychiatric Institute
·
Phase 2
·
NCT05273567
·
22 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
3 trial records for guanfacine-ER. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
guanfacine-ER compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for guanfacine-ER. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Yale University company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Phase 2
[1]
Company
Y
Yale University
Related News